AMGN
AmgenstockAMGN · 90-day price history
Prediction models
All predictions →Trend follower
Horizon: 1 week
Accuracy data accumulates as predictions are evaluated over time.
How this worksHide explanation
Compares a 10-day vs 50-day moving average. When the short-term average rises above the long-term average, the trend is up.
Not financial advice. Past accuracy does not guarantee future results.
Momentum
Horizon: 1 week
Accuracy data accumulates as predictions are evaluated over time.
How this worksHide explanation
Uses RSI (a gauge of recent buying/selling intensity) and 5-day rate-of-change to judge whether the stock has been pushed too far in one direction.
Not financial advice. Past accuracy does not guarantee future results.
Statistical trend
Horizon: 1 month
Accuracy data accumulates as predictions are evaluated over time.
How this worksHide explanation
Fits a trend line through the last 60 days of prices and measures how far the current price has strayed from it.
Not financial advice. Past accuracy does not guarantee future results.
Bull / Bear thesis
AI analysisStock surged 4.84% today, a major outperformer
Amgen rose 4.84% significantly beating the broader market
Price actionNew Phase 3 data shows cardiovascular benefit
Amgen presented Phase 3 data showing Repatha significantly reduces cardiovascular risk in diabetes patients
NewsOne of top large-cap value stocks according to analysts
Analysts highlight Amgen as one of the top large-cap value stocks to buy
NewsKey drug faces FDA withdrawal fight
Tavneos faces potential FDA withdrawal due to approval questions and safety concerns
NewsRegulatory headwinds from new drug
Amgen had to bring in Duke for independent review of Tavneos data
NewsValuation already reflects improvement
After significant outperformance, stock may be pricing in much of the good news
NewsAI-generated from recent news and price action. Not financial advice. Educational only.
Recent news
Yahoo · Jun 12
When a major drug faces FDA issues, it creates uncertainty that can offset other positive developments.
Yahoo · Jun 11
Strong Phase 3 cardiovascular data could expand Repatha's market opportunity beyond its current scope, driving long-term sales.
AI research companion
AI Research Companion
Loading…
Ready to paper trade AMGN?
Switch to Portfolio mode to buy and sell with $100k of simulated funds.